Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Revenue (2016 - 2025)

Ocular Therapeutix has reported Revenue over the past 13 years, most recently at $13.2 million for Q4 2025.

  • Quarterly results put Revenue at $13.2 million for Q4 2025, down 22.43% from a year ago — trailing twelve months through Dec 2025 was $52.0 million (down 18.47% YoY), and the annual figure for FY2025 was $52.0 million, down 18.47%.
  • Revenue for Q4 2025 was $13.2 million at Ocular Therapeutix, down from $14.5 million in the prior quarter.
  • Over the last five years, Revenue for OCUL hit a ceiling of $17.1 million in Q4 2024 and a floor of $7.3 million in Q1 2021.
  • Median Revenue over the past 5 years was $13.4 million (2023), compared with a mean of $13.5 million.
  • Biggest five-year swings in Revenue: skyrocketed 646.85% in 2021 and later dropped 27.59% in 2025.
  • Ocular Therapeutix's Revenue stood at $12.3 million in 2021, then rose by 14.36% to $14.1 million in 2022, then increased by 5.16% to $14.8 million in 2023, then increased by 15.41% to $17.1 million in 2024, then decreased by 22.43% to $13.2 million in 2025.
  • The last three reported values for Revenue were $13.2 million (Q4 2025), $14.5 million (Q3 2025), and $13.5 million (Q2 2025) per Business Quant data.